Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 18 de 18
Filter
1.
Rev Bras Enferm ; 73(6): e20190680, 2020 Sep 07.
Article in English, Portuguese | MEDLINE | ID: mdl-32901750

ABSTRACT

OBJECTIVE: To analyze the HIV care continuum from the diagnosis in an HIV/AIDS Counseling and Testing Center (CTC), and the sociodemographic, clinical, and laboratory characteristics related to gender. METHOD: Epidemiological study, conducted with data of individuals assisted at a Counseling and Testing Center, and followed in an outpatient clinic for HIV/AIDS. Pearson's Chi-square test and binary logistic regression were used to obtain odds ratios, considering alpha value <0.05. RESULTS: The prevalence of HIV among 5,229 users was 5%. The highest chance of positive results was among men, aged 14 to 33 years old, who were not in a domestic partnership. In the analysis of TCD4+ lymphocytes and viral load (VL) of 238 cases, 56.1% had a late diagnosis. We have identified gaps in the care cascade, especially linkage to the care, retention in care, and viral load suppression. CONCLUSION: The results suggest a late diagnosis for both genders, as well as difficulty in reaching the viral suppression goal.


Subject(s)
HIV Infections , Adolescent , Adult , Continuity of Patient Care , Counseling , Delayed Diagnosis , Female , HIV Infections/diagnosis , HIV Infections/epidemiology , Humans , Male , Viral Load , Young Adult
2.
Rev. bras. enferm ; 73(6): e20190680, 2020. tab, graf
Article in English | LILACS, BDENF - Nursing | ID: biblio-1125881

ABSTRACT

ABSTRACT Objective: To analyze the HIV care continuum from the diagnosis in an HIV/AIDS Counseling and Testing Center (CTC), and the sociodemographic, clinical, and laboratory characteristics related to gender. Method: Epidemiological study, conducted with data of individuals assisted at a Counseling and Testing Center, and followed in an outpatient clinic for HIV/AIDS. Pearson's Chi-square test and binary logistic regression were used to obtain odds ratios, considering alpha value <0.05. Results: The prevalence of HIV among 5,229 users was 5%. The highest chance of positive results was among men, aged 14 to 33 years old, who were not in a domestic partnership. In the analysis of TCD4+ lymphocytes and viral load (VL) of 238 cases, 56.1% had a late diagnosis. We have identified gaps in the care cascade, especially linkage to the care, retention in care, and viral load suppression. Conclusion: The results suggest a late diagnosis for both genders, as well as difficulty in reaching the viral suppression goal.


RESUMEN Objetivo: Analizar la cascada del cuidado del VIH a partir del diagnóstico en Centro de Pruebas y Consejo (CTA); y las características sociodemográficas, clínicas y laboratoriales relacionadas al sexo. Método: Estudio epidemiológico, realizado con datos de indivíduos atendidos en un Centro de Pruebas y Consejo y acompañados en ambulatorio de VIH/sida. Han sido utilizados el test chi cuadrado y regresión logística binaria, para obtención del odds ratio, considerando alfa < 0,05. Resultados: La prevalencia de VIH nos 5.229 usuarios ha sido de 5%, con mayor chance de resultado positivo entre hombres, franja etaria de 14 a 33 años, que no presentaban unión estable. En el análisis de linfocitos TCD4+ y carga viral (CV) de 238 casos, 56,1% realizaron diagnóstico tardío. Han sido identificadas lagunas en la cascada del cuidado, especialmente en la vinculación, retención en el cuidado y supresión de la carga viral. Conclusión: Los resultados sugieren diagnóstico tardío para ambos los sexos, además dificultad en alcanzar la meta de supresión viral.


RESUMO Objetivo: Analisar a cascata do cuidado do HIV a partir do diagnóstico em Centro de Testagem e Aconselhamento (CTA); e as características sociodemográficas, clínicas e laboratoriais relacionadas ao sexo. Método: Estudo epidemiológico, realizado com dados de indivíduos atendidos num Centro de Testagem e Aconselhamento e acompanhados em ambulatório de HIV/aids. Foram utilizados o teste Qui-quadrado e regressão logística binária, para obtenção do odds ratio, considerando alfa < 0,05. Resultados: A prevalência de HIV nos 5.229 usuários foi de 5%, com maior chance de resultado positivo entre homens, faixa etária de 14 a 33 anos, que não apresentavam união estável. Na análise de linfócitos TCD4+ e carga viral (CV) de 238 casos, 56,1% realizaram diagnóstico tardio. Foram identificadas lacunas na cascata do cuidado, especialmente na vinculação, retenção no cuidado e supressão da carga viral. Conclusão: Os resultados sugerem diagnóstico tardio para ambos os sexos, além de dificuldade em alcançar a meta de supressão viral.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Young Adult , HIV Infections , HIV Infections/diagnosis , HIV Infections/epidemiology , Continuity of Patient Care , Viral Load , Counseling , Delayed Diagnosis
3.
Rev. Saúde Pública Paraná (Online) ; 2(2): 39-48, 10 dezembro de 2019.
Article in Portuguese | CONASS, SESA-PR, Coleciona SUS | ID: biblio-1128554

ABSTRACT

O objetivo do trabalho foi avaliar fatores sociodemográficos e laboratoriais dos pacientes infectados pelo HIV em uso de terapia antirretroviral (TARV) associados ao Índice de Desenvolvimento Humano Municipal (IDHM). O estudo envolveu 4.900 pacientes de 116 municípios do Paraná, atendidos no período de 2012 a 2015. Os pacientes foram divididos em três grupos de acordo com o tamanho e o IDHM do município de residência. Cidades de pequeno porte/IDHM médio apresentaram taxas mais elevadas de mulheres, indivíduos mais jovens e baixa escolaridade, quando comparadas com as cidades de grande porte/IDHM alto. As taxas totais de resposta imunológica, virológica e completa à TARV foram de 71,9%, 68,2% e 57,1%, respectivamente, com melhores resultados para o grupo vivendo em municípios de grande porte/IDHM alto. Apesar dessas diferenças, as respostas imunológica e virológica foram semelhantes entre os grupos, sugerindo que o grau de desenvolvimento do município não está associado com a efetividade da terapia para o HIV-1. (AU)


The objective of the study was to evaluate sociodemographic and laboratory factors of HIV patients on use of antiretroviral therapy (cART) associated with the Municipal Human Development Index (IDHM). The study enrolled 4,900 HIV-patients from 116 municipalities in the state of Paraná, in the South of Brazil, attended from 2012 to 2015. Patients were divided into three groups according to the size and the IDHM of the city of origin. Small sized/medium-IDHM cities showed higher rates of women, individuals with low educational level and young age, when compared to large sized/high-IDHM ones. The general rates of immunologic, virologic and complete responses to cART were of 71.9%, 68.2% and 57.1%, respectively, and better results were observed in the group from large size/high-IDHM cities. Despite these differences, immunologic and virologic responses were similar between the groups, demonstrating that the municipality level of development is not associated with the effectiveness of HIV-1 therapy. (AU)


Subject(s)
Humans , Male , Female , Effectiveness , Monitoring, Immunologic , Public Health , HIV-1 , Development Indicators , Antiretroviral Therapy, Highly Active
4.
Cad Saude Publica ; 34(12): e00009718, 2018 11 29.
Article in English | MEDLINE | ID: mdl-30517309

ABSTRACT

The cascade of care for people living with HIV infection (PLHIV) describes steps in diagnosis, linkage and retention in care, as well as the provision and success of combination antiretroviral therapy (cART). The aim of this study was to evaluate the rates regarding the retention in care, on cART, and suppressed viral load for PLHIV attended at a Brazilian public health network. Data on PLHIV from 116 cities of Paraná, Southern Brazil, attended from 2012 to 2015, were retrospectively collected through the Laboratory Tests Control System (SISCEL). The number of PLHIV related to care increased about 22.5% from 2012 to 2015 (4,106 to 5,030 individuals). The proportion of PLHIV retained in care showed a trend toward stabilization around 81.7-86.9%. Every year, the use of cART increased up to 90.3% for PLHIV retained in care. Viral load suppression was achieved by 72.8% of patients on cART and 57.1% by those linked to care. Retention in care and HIV viral suppression were more likely to occur in older PLHIV than younger ones; similarly, patients living in medium-sized cities were more susceptible to these factors than in large- or small-sized cities. In conclusion, the study showed a high level of retention in care and HIV suppression on cART, as well as emphasized that current efforts for treating already-infected PLHIV remain a challenge for our health public institutions and may contribute to highlight steps for improvement of the HIV cascade of care in our population.


Subject(s)
Anti-HIV Agents/therapeutic use , Continuity of Patient Care , HIV Infections/diagnosis , HIV Infections/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Brazil , CD4 Lymphocyte Count , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Middle Aged , Public Health , Retrospective Studies , Sustained Virologic Response , Viral Load , Young Adult
5.
Cad Saude Publica ; 34(10): e00009618, 2018 10 22.
Article in English | MEDLINE | ID: mdl-30365742

ABSTRACT

The latest Brazilian guideline recommended the reduction of routine CD4+ T cell counts for the monitoring of patients with human immunodeficiency virus type 1 (HIV-1) under combination antiretroviral therapy (cART). The aim of this study was to evaluate the safety of monitoring response to cART in HIV-1 infection using routine viral load at shorter intervals and CD4+ T cell count at longer intervals. CD4+ T cell counts and HIV-1 viral load were evaluated in 1,906 HIV-1-infected patients under cART during a three-year follow-up. Patients were stratified as sustained, non-sustained and non-responders. The proportion of patients who showed a CD4+ T > 350cells/µL at study entry among those with sustained, non-sustained and non-responders to cART and who remained with values above this threshold during follow-up was 94.1%, 81.8% and 71.9%, respectively. HIV-1-infected patients who are sustained virologic responders and have initial CD4+ T cell counts > 350cells/µL showed a higher chance of maintaining the counts of these cells above this threshold during follow-up than those presenting CD4+ T ≤ 350cells/µL (OR = 39.9; 95%CI: 26.5-60.2; p < 0.001). This study showed that HIV-1-infected patients who had sustained virologic response and initial CD4+ T > 350cells/µL were more likely to maintain CD4+ T cell counts above this threshold during the next three-year follow-up. This result underscores that the evaluation of CD4+ T cell counts in longer intervals does not impair the safety of monitoring cART response when routine viral load assessment is performed in HIV-1-infected patients with sustained virologic response.


Subject(s)
Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , CD4 Lymphocyte Count/methods , HIV Infections/drug therapy , HIV-1/immunology , Adolescent , Adult , Anti-HIV Agents/adverse effects , Antiretroviral Therapy, Highly Active/adverse effects , Female , Follow-Up Studies , HIV-1/drug effects , Humans , Longitudinal Studies , Male , Middle Aged , Socioeconomic Factors , Time Factors , Viral Load/drug effects , Viral Load/immunology , Young Adult
6.
Cad. Saúde Pública (Online) ; 34(10): e00009618, oct. 2018. tab, graf
Article in English | LILACS | ID: biblio-974575

ABSTRACT

Abstract: The latest Brazilian guideline recommended the reduction of routine CD4+ T cell counts for the monitoring of patients with human immunodeficiency virus type 1 (HIV-1) under combination antiretroviral therapy (cART). The aim of this study was to evaluate the safety of monitoring response to cART in HIV-1 infection using routine viral load at shorter intervals and CD4+ T cell count at longer intervals. CD4+ T cell counts and HIV-1 viral load were evaluated in 1,906 HIV-1-infected patients under cART during a three-year follow-up. Patients were stratified as sustained, non-sustained and non-responders. The proportion of patients who showed a CD4+ T > 350cells/µL at study entry among those with sustained, non-sustained and non-responders to cART and who remained with values above this threshold during follow-up was 94.1%, 81.8% and 71.9%, respectively. HIV-1-infected patients who are sustained virologic responders and have initial CD4+ T cell counts > 350cells/µL showed a higher chance of maintaining the counts of these cells above this threshold during follow-up than those presenting CD4+ T ≤ 350cells/µL (OR = 39.9; 95%CI: 26.5-60.2; p < 0.001). This study showed that HIV-1-infected patients who had sustained virologic response and initial CD4+ T > 350cells/µL were more likely to maintain CD4+ T cell counts above this threshold during the next three-year follow-up. This result underscores that the evaluation of CD4+ T cell counts in longer intervals does not impair the safety of monitoring cART response when routine viral load assessment is performed in HIV-1-infected patients with sustained virologic response.


Resumo: O último consenso brasileiro recomenda reduzir a rotina de contagem de linfócitos T CD4+ para monitorar os pacientes com HIV-1 sob terapia antirretroviral combinada (TARV). O estudo teve como objetivo avaliar a segurança do monitoramento à TARV na infecção pelo HIV-1, realizando a carga viral a intervalos mais curtos e a contagem de linfócitos T CD4+ a intervalos mais longos. Foram avaliadas a contagem de linfócitos T CD4+ e a carga viral do HIV-1 em 1.906 pacientes com HIV-1 em uso de TARV durante um seguimento de três anos. Os pacientes foram estratificados em: resposta sustentada, não sustentada e não respondedores. As proporções de pacientes com linfócitos T CD4+ > 350células/µL na linha de base do estudo entre de resposta sustentada, não sustentada e não respondedores à TARV e que permaneceram com valores acima desse limiar ao longo do seguimento foram 94,1%, 81,8% e 71,9%, respectivamente. Os pacientes com resposta virológica sustentada e que tinham contagem de T CD4+ > 350células/µL mostraram maior probabilidade de manter a contagem acima desse limiar durante o seguimento, quando comparados àqueles com T CD4+ ≤ 350células/µL (OR = 39,9; 95%CI: 26,5-60,2; p < 0,001). O estudo mostrou que pacientes HIV-1+ com resposta virológica sustentada e contagem de linfócitos T CD4+ > 350células/µL tinham maior probabilidade de manter a contagem de células T CD4+ acima desse limiar durante o seguimento de três anos subsequentes. O resultado corrobora que a contagem de linfócitos T CD4+ com intervalos mais longos não compromete a segurança do monitoramento da resposta à TARV quando a avaliação da carga viral é feita de rotina em pacientes HIV-1+ com resposta virológica sustentada.


Resumen: Las últimas directrices brasileñas recomendaron la reducción de la rutina en el recuento celular CD4+ T para pacientes con el virus de inmunodeficiencia humano tipo 1 (VIH-1), con terapia de combinación antirretroviral (cART por sus siglas en inglês). El objetivo de este estudio fue evaluar la seguridad de la monitorización de la respuesta a la cART en una infección por VIH-1, usando rutinas de carga viral en intervalos más cortos y recuento celular CD4+ T en intervalos más largos. Se evaluaron el recuento celular CD4+ T y la carga viral VIH-1 en 1.906 pacientes infectados con VIH-1 y con cART durante un seguimiento que duró tres años. Los pacientes fueron estratificados como constantes, inconstantes y sin respuesta. La proporción de pacientes que mostraron CD4+ T > 350células/µL en el estudio entran dentro del grupo de los constantes, inconstantes y sin respuesta al cART, y quienes permanecieron con valores por encima de este umbral durante los seguimientos fueron 94,1%, 81,8% y 71,9%, respectivamente. Los pacientes infectados por VIH-1 que cuentan con la respuesta virológica constante y tienen un recuento inicial CD4+ T > 350células/µL mostraron una oportunidad más alta de mantener el recuento de estas células por encima del umbral durante los seguimientos, respecto a quienes presentaban CD4+ T células ≤ 350células/µL (OR = 39,9; IC95%: 26,5-60,2; p < 0,001). Este estudio expuso que los pacientes infectados por VIH-1, que habían tenido una respuesta virológica constante e inicial CD4+ T > 350células/µL, eran más propensos a mantener el recuento de células CD4+ T por encima de este umbral durante los tres años posteriores de seguimiento. Este resultado destaca que la evaluación del cómputo de células CD4+ T en intervalos más largos no obstaculiza la seguridad al realizar una monitorización en la respuesta a cART, cuando la evaluación de la carga viral rutinaria se realiza en pacientes infectados por VIH-1 con una respuesta virológica constante.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , HIV Infections/drug therapy , HIV-1/immunology , CD4 Lymphocyte Count/methods , Anti-HIV Agents/administration & dosage , Antiretroviral Therapy, Highly Active/methods , Socioeconomic Factors , Time Factors , Follow-Up Studies , Longitudinal Studies , HIV-1/drug effects , Anti-HIV Agents/adverse effects , Viral Load/drug effects , Viral Load/immunology , Antiretroviral Therapy, Highly Active/adverse effects , Middle Aged
7.
Cad. Saúde Pública (Online) ; 34(12): e00009718, 2018. tab, graf
Article in English | LILACS | ID: biblio-974617

ABSTRACT

Abstract: The cascade of care for people living with HIV infection (PLHIV) describes steps in diagnosis, linkage and retention in care, as well as the provision and success of combination antiretroviral therapy (cART). The aim of this study was to evaluate the rates regarding the retention in care, on cART, and suppressed viral load for PLHIV attended at a Brazilian public health network. Data on PLHIV from 116 cities of Paraná, Southern Brazil, attended from 2012 to 2015, were retrospectively collected through the Laboratory Tests Control System (SISCEL). The number of PLHIV related to care increased about 22.5% from 2012 to 2015 (4,106 to 5,030 individuals). The proportion of PLHIV retained in care showed a trend toward stabilization around 81.7-86.9%. Every year, the use of cART increased up to 90.3% for PLHIV retained in care. Viral load suppression was achieved by 72.8% of patients on cART and 57.1% by those linked to care. Retention in care and HIV viral suppression were more likely to occur in older PLHIV than younger ones; similarly, patients living in medium-sized cities were more susceptible to these factors than in large- or small-sized cities. In conclusion, the study showed a high level of retention in care and HIV suppression on cART, as well as emphasized that current efforts for treating already-infected PLHIV remain a challenge for our health public institutions and may contribute to highlight steps for improvement of the HIV cascade of care in our population.


Resumo: A cascata de cuidados para pessoas vivendo com a infecção pelo HIV (PVHIV) representa os passos no diagnóstico, vínculo e retenção em tratamento, assim como, no fornecimento e resultado da terapia antirretroviral combinada (TARVc). O estudo teve como objetivo avaliar as taxas relativas à retenção em atendimento, uso de TARVc e supressão da carga viral em PVHIV atendidas em uma rede pública de saúde. Através do Sistema de Controle de Exames Laboratoriais (SISCEL), os dados foram coletados retrospectivamente, referentes às PVHIV de 116 municípios no Estado do Paraná, Sul do Brasil, atendidas entre 2012 e 2015. O número de PVHIV vinculadas ao atendimento aumentou em 22,5% entre 2012 e 2015 (de 4.106 para 5.030 indivíduos). A proporção de PVHIV retidas no atendimento mostrou uma tendência de estabilização, em torno de 81,7-86,9%. O uso de TARVc aumentou a cada ano, chegando a 90,3% das PVHIV retidas em atendimento. A supressão da carga viral foi alcançada por 72,8% dos pacientes em uso de TARVc e em 57,1% daqueles vinculados ao atendimento. A retenção no atendimento e a supressão da carga viral foram mais frequentes em PVHIV mais velhas e em pacientes residentes em municípios de porte médio. Em conclusão, o estudo mostrou um nível elevado de retenção em atendimento e de supressão da carga viral na vigência do uso de TARVc, além de enfatizar que os esforços atuais de tratamento das PVHIV ainda são um desafio para as instituições de saúde pública, podendo ajudar a identificar passos para melhorar a cascata de cuidados em HIV para a população.


Resumen: Este trabajo describe los pasos en la diagnosis, vinculación y retención en el cuidado, así como la provisión y éxito de la terapia antirretroviral combinada (cART por sus siglas en inglés) para personas que viven con una infección de VIH (PLHIV por sus siglas en inglés). El objetivo de este estudio fue evaluar las tasas en relación con la retención en el cuidado, terapia antirretroviral combinada y carga viral eliminada de las personas que viven con una infección de VIH, y reciben atención en la red pública de salud brasileña. Los datos de PLHIV procedieron de 116 ciudades de Paraná, sur de Brasil, desde 2012 a 2015, se recogieron retrospectivamente a través del Sistema de Control de Exámenes de Laboratorio (SISCEL). El número de PLHIV informado con necesidad de cuidados se incrementó un 22,5% de 2012 a 2015 (de 4.106 a 5.030 individuos). La proporción de PLHIV que fue constante en el cuidado mostró una tendencia hacia la estabilización de alrededor de un 81,7 a un 86,9%. Cada año, el uso del cART se incrementó hasta un 90,3% en el caso de PLHIV que fueron constantes en sus cuidados. La eliminación de la carga viral se consiguió en un 72,8% de los pacientes con cART y en un 57,1% por parte de aquellos vinculados a cuidados. La constancia en el cuidado y la eliminación de la carga viral en VIH eran más factibles de producirse en PLHIV más viejas que en las jóvenes; de igual forma, los pacientes que vivían en ciudades de tamaño medio eran más susceptibles hacia estos factores que en ciudades más grandes o pequeñas. Como conclusión, el estudio mostró un alto nivel de constancia en el cuidado y la eliminación de carga viral del HIV con cART, asimismo enfatizó que los actuales esfuerzos para tratar a las PLHIV ya infectadas continuaba siendo un desafío para nuestras instituciones públicas de salud y quizás podría contribuir a resaltar los pasos necesarios hacia la mejora de la serie de cuidados en VIH sobre nuestra población.


Subject(s)
Humans , Male , Female , Infant, Newborn , Infant , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , HIV Infections/diagnosis , HIV Infections/therapy , Continuity of Patient Care , Anti-HIV Agents/therapeutic use , Brazil , Public Health , Retrospective Studies , CD4 Lymphocyte Count , Viral Load , Sustained Virologic Response
10.
Rev. bras. hematol. hemoter ; 33(5): 347-352, Oct. 2011. tab
Article in English | LILACS | ID: lil-606710

ABSTRACT

BACKGROUND: For transfusion purposes, blood donors must be accepted both in clinical and serological evaluations and must not have excluded their own donation using the confidential unit exclusion. AIMS: The objective of this study was to verify whether blood donors who choose self exclusion are more likely to be positive in serological tests than donors who do not. METHODS: A cross-sectional analysis was carried out of 51,861 consecutive whole blood donations from January 2004 to December 2008 at a public blood bank in Londrina, Southern Brazil. RESULTS: Self exclusion was chosen in 1672 (3.2 percent) donations, most frequently by first-time blood donors (p-value < 0.0001), by blood donors from external collections (p-value < 0.0001), by men (p value < 0.0001) and by under 30-year-old donors (p-value < 0.0001). The frequency of positive serology was 5.3 percent in the group that chose self exclusion and 3.5 percent in the group that did not choose self exclusion (p-value < 0.0001). CONCLUSIONS: These results show that confidential unit exclusion used in this blood bank is effective and is inexpensive. However, the diagnostic power to detect blood-borne infections was low and resulted in the discard of a high number of blood bags without any direct or indirect serologic markers of pathogens. The use of confidential unit exclusion could be replaced with molecular tests to screen blood donors.


Subject(s)
Humans , Male , Female , Blood Donors , Blood Transfusion , Serologic Tests
11.
Rev Bras Hematol Hemoter ; 33(5): 347-52, 2011.
Article in English | MEDLINE | ID: mdl-23049338

ABSTRACT

BACKGROUND: For transfusion purposes, blood donors must be accepted both in clinical and serological evaluations and must not have excluded their own donation using the confidential unit exclusion. AIM: The objective of this study was to verify whether blood donors who choose self exclusion are more likely to be positive in serological tests than donors who do not. METHODS: A cross-sectional analysis was carried out of 51,861 consecutive whole blood donations from January 2004 to December 2008 at a public blood bank in Londrina, Southern Brazil. RESULTS: Self exclusion was chosen in 1672 (3.2%) donations, most frequently by first-time blood donors (p-value < 0.0001), by blood donors from external collections (p-value < 0.0001), by men (p value < 0.0001) and by under 30-year-old donors (p-value < 0.0001). The frequency of positive serology was 5.3% in the group that chose self exclusion and 3.5% in the group that did not choose self exclusion (p-value < 0.0001). CONCLUSIONS: These results show that confidential unit exclusion used in this blood bank is effective and is inexpensive. However, the diagnostic power to detect blood-borne infections was low and resulted in the discard of a high number of blood bags without any direct or indirect serologic markers of pathogens. The use of confidential unit exclusion could be replaced with molecular tests to screen blood donors.

12.
Int J Mol Med ; 21(3): 387-95, 2008 Mar.
Article in English | MEDLINE | ID: mdl-18288387

ABSTRACT

A cross-sectional study was carried out in order to describe the epidemiological, immunological and virological characteristics, and the disease progression of hepatitis C virus (HCV)/human immunodeficiency virus type 1 (HIV-1)- co-infected patients from a southern Brazilian population. Of 778 HIV-1-infected individuals enrolled in the study from September 2001 to December 2003, and followed up until June 2004, 757 were tested for anti-HCV antibodies. Of these, 159 (21.0%) showed positive results for anti-HCV. Males, individuals in the 25 to 34 year age range, and individuals of lower economic levels were more likely to be seropositive for both viruses [prevalence rate (PR), 2.04; 95% confidence interval (95% CI), 1.43-2.92; p<0.001]. The anti-HCV reactivity was also associated with blood routes of transmission (PR, 2.20; 95% CI, 1.28-3.77; p<0.001), intravenous drug use (PR, 5.79; 95% CI, 4.74-7.07; p<0.001), self-reported previous sexually transmitted diseases (PR, 1.55; 95% CI, 1.18-2.04; p=0.002), VDRL positivity (PR, 2.87; 95% CI, 2.40-3.43; p<0.001), and anti-HTLV I/II reactivity (PR, 5.09; 95% CI, 4.16-6.23; p<0.001). In the follow-up period, the HCV/HIV-1-co-infected patients showed a trend toward lower CD4+ T-cell counts, higher HIV-1 RNA plasma viral load and faster disease progression than patients infected only with HIV-1, but significant differences were not observed. Although there were proportionately more deaths in the HCV/HIV-1-co-infected group, the use of highly active antiretroviral therapy (HAART) was a string predictor of increased CD4+ T-cell counts and decreased HIV-1 RNA plasma levels, suggesting that HAART is more important to the immunological and virological outcomes in HIV-1 infection than is HCV co-infection status.


Subject(s)
HIV Infections/complications , HIV Infections/epidemiology , HIV-1/immunology , Hepacivirus/immunology , Hepatitis C/complications , Hepatitis C/epidemiology , Adolescent , Adult , Brazil/epidemiology , CD4 Lymphocyte Count , Disease Progression , Female , HIV Infections/immunology , HIV Infections/virology , HIV Seropositivity , Hepatitis C/immunology , Hepatitis C/virology , Humans , Male , RNA, Viral/blood , Survival Analysis
13.
Semina cienc. biol. saude ; 28(1): 23-32, jan.-jun. 2007. tab
Article in Portuguese | LILACS | ID: lil-479981

ABSTRACT

As imunoglobulinas constituem um grupo de glicoproteínas presentes no soro e nos líquidos orgânicos e são produzidas pelos linfócitos B ativados que se diferenciam em plasmócitos. São divididas em cinco classes ou isotipos: IgG, IgA, IgM, IgD e IgE. O objetivo deste trabalho foi determinar a freqüência das alterações dos níveis séricos das imunoglobulinas nos pacientes atendidos pelo Hospital Universitário (HU), Londrina, PR, no período de agosto de 2001 a fevereiro de 2006, avaliados pelo método de nefelometria. Foram analisadas 773 amostras de soro de pacientes, 410 (53,0%) do sexo feminino e 363 (47,0%) do sexo masculino, com idade variando de um mês a 86 anos. Das 1719 dosagens de imunoglobulinas séricas realizadas, os níveis de IgA sérica foram avaliados em 568 amostras e foram observadas alterações em 88 (15,5%) das amostras. Das 495 dosagens de IgG, 107 (21,6%) estavam com os níveis séricos alterados. A dosagem de IgM sérica foi realizada em 465 amostras e 142 (30,5%) estavam com os níveis séricos alterados. Os níveis de IgE sérica foram avaliados em 191 amostras e 129 (67,5%) amostras apresentaram níveis aumentados. Os dados obtidos confirmam a ocorrência de diferentes alterações nos níveis séricos das imunoglobulinas e a importância destas dosagens laboratoriais no diagnóstico de doenças infecciosas, parasitárias, alérgicas, auto-imunes e das imunodeficiências humorais congênitas ou adquiridas.


Subject(s)
Immunoglobulins , Multiple Myeloma , Immunologic Deficiency Syndromes
14.
Int J Mol Med ; 18(4): 785-93, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16964435

ABSTRACT

The human immunodeficiency virus type 1 (HIV-1) epidemic is increasing in Brazil, and little information has been reported about the genetic host factors related to HIV-1 infection in the Brazilian population. A polymorphism in the conserved 3' untranslated region of the stromal cell-derived factor 1 (SDF1/CXCL12) gene has been related either to resistance to HIV-1 infection and delayed progression to AIDS or to rapid disease progression and death. A longitudinal study was conducted to evaluate the association of the SDF1 polymorphism and the progression of HIV-1 infection in 161 asymptomatic patients infected with HIV-1 (ASYMPT) and 617 patients with AIDS (SYMPT) from Londrina and the surrounding region, southern Brazil. The endpoints used were the development of AIDS, death, and the slopes of the CD4+ T cell counts and HIV-1 RNA plasma levels. Among the 161 ASYMPT patients, all of the 7 patients (4.3%) homozygous for the mutation remained asymptomatic (p=0.1906); 6 of them had not initiated antiretroviral therapy. Among the 617 patients with AIDS, 40 (6.5%) progressed to death. Of these, 33/388 (8.5%) did not have the SDF1-3'A allele, 6/196 (3.1%) were heterozygous and 1/33 (3.0%) was homozygous for the SDF1-3'A allele (p=0.029). The SDF1 genotypes were not associated with the surrogate markers of HIV-1 disease progression such as the CD4+ T cell decline and plasma HIV-1 RNA levels. The results observed in this study support the hypothesis that the mutation of SDF1-3'A could have a possible late-stage protective effect on HIV-1 disease progression in the Brazilian population.


Subject(s)
Chemokines, CXC/genetics , HIV Infections/genetics , HIV-1/growth & development , Polymorphism, Genetic/genetics , Adolescent , Adult , Aged , Alleles , Analysis of Variance , Brazil/epidemiology , CD4 Lymphocyte Count , Chemokine CXCL12 , Disease Progression , Female , Gene Frequency , Genotype , HIV Infections/blood , HIV Infections/epidemiology , HIV-1/genetics , Humans , Male , Middle Aged , Mutation/genetics , Polymorphism, Restriction Fragment Length , RNA, Viral/blood
15.
Rev. Inst. Med. Trop. Säo Paulo ; 46(6): 303-308, Nov.-Dec. 2004. tab
Article in English | LILACS | ID: lil-391585

ABSTRACT

Aspectos sorológicos, epidemiológicos e moleculares da infecção pelo vírus da hepatite C (HCV) foram avaliados em 183 indivíduos da região de Londrina, Paraná. Amostras soropositivas para anti-HCV pelo enzimaimunoensaio de micropartículas (MEIA), provenientes de oito pacientes com hepatite C crônica, 48 doadores de sangue e 127 indivíduos infectados pelo vírus da imunodeficiência humana (HIV), foram submetidas ao enzimaimunoensaio (ELISA) e a reação em cadeia da polimerase (PCR). Em 78,7% das amostras, verificou-se resultado reagente no ELISA, ocorrendo maior proporção de resultados discordantes entre doadores de sangue (70,8%). O mesmo ocorreu com a pesquisa do RNA viral, na qual 111/165 (67,3%) amostras foram positivas com PCR, verificando-se maior positividade entre indivíduos HIV soropositivos e pacientes com hepatite crônica do que em doadores de sangue. Em 61 amostras com viremia detectável, realizou-se a genotipagem do HCV, encontrando-se os genótipos 1 (77,1%), 3 (21,3%) e 2 (1,6%). Por fim, foram avaliados os fatores epidemiológicos em indivíduos com infecção ativa, nos quais o uso de drogas injetáveis foi o principal fator de risco encontrado em indivíduos co-infectados pelo HIV/HCV e a transfusão sangüínea foi o mais comum em indivíduos sem infecção pelo HIV. O presente estudo contribuiu para o conhecimento do perfil da infecção pelo HCV em indivíduos da nossa população e da distribuição dos genótipos do HCV nesta região.


Subject(s)
Humans , Hepacivirus , Hepatitis C , Hepatitis C Antibodies , Blood Donors , Brazil , Chronic Disease , Genotype , Hepatitis C , HIV Infections , Immunoenzyme Techniques , Polymerase Chain Reaction , Prevalence , Risk Factors , RNA, Viral , Seroepidemiologic Studies
16.
Rev Inst Med Trop Sao Paulo ; 46(6): 303-8, 2004.
Article in English | MEDLINE | ID: mdl-15654474

ABSTRACT

Serological, epidemiological and molecular aspects of hepatitis C virus (HCV) infection were evaluated in 183 subjects from Londrina, Paraná, Brazil, and adjacent areas. Serum samples which tested anti-HCV positive by microparticle enzyme immunoassay (MEIA) obtained from eight patients with chronic hepatitis C, 48 blood donors, and 127 patients infected with the human immunodeficiency virus (HIV) were submitted to another enzyme immunoassay (ELISA) and to the polymerase chain reaction (PCR). About 78.7% of samples were also reactive by ELISA, with the greater proportion (70.8%) of discordant results verified among blood donors. A similar finding was observed for HCV-RNA detection by PCR, with 111/165 (67.3%) positive samples, with higher rates among HIV-positive subjects and patients with chronic hepatitis than among blood donors. Sixty-one PCR-positive samples were submitted to HCV genotyping, with 77.1, 21.3 and 1.6% of the samples identified as types 1, 3 and 2, respectively. Finally, analysis of some risk factors associated with HCV infection showed that intravenous drug use was the most common risk factor among HIV/HCV co-infected patients, while blood transfusion was the most important risk factor in the group without HIV infection. The present study contributed to the knowledge regarding risk factors associated with HCV infection and the distribution of HCV genotypes in the population evaluated.


Subject(s)
Hepacivirus/immunology , Hepatitis C Antibodies/blood , Hepatitis C/epidemiology , Blood Donors , Brazil/epidemiology , Genotype , HIV Infections/complications , Hepacivirus/genetics , Hepatitis C/diagnosis , Hepatitis C/transmission , Humans , Prevalence , Risk Factors , Seroepidemiologic Studies
17.
Rev Inst Med Trop Sao Paulo ; 45(1): 23-7, 2003.
Article in English | MEDLINE | ID: mdl-12751318

ABSTRACT

This study evaluated the usefulness of the anti-HBc, hepatitis C virus antibodies (anti-HCV), human T cell lymphotropic virus I and II antibodies (anti-HTLV I/II), serologic tests for syphilis, and surface antigen of hepatitis B virus (HBsAg) as surrogate markers for the risk for HIV infection in 80,284 serum samples from blood donors from the Blood Bank of "Hospital Universitário Regional Norte do Paraná", Londrina, Paraná State, Brazil, analyzed from July 1994 to April 2001. Among 39 blood donors with positive serology for HIV, 12 (30.8%) were anti-HBc positive, 10 (25.6%) for anti-HCV, 1 (2.6%) for anti-HTLV I/I, 1 (2.6%) was positive for syphilis, and 1 (2.6%) for HBsAg. Among the donors with negative serology for HIV, these markers were detected in 8,407 (10.5%), 441 (0.5%), 189 (0.2%), 464 (0.6%), and 473 (0.6%) samples, respectively. The difference was statistically significant (p < 0.001) for anti-HBc and anti-HCV. Although the predictive positive values for these surrogate markers were low for HIV infection, the results confirmed the anti-HBc and anti-HCV as useful surrogate markers for HIV infection thus reinforcing the maintenance of them in the screening for blood donors contributing to the prevention of the small number of cases in which HIV is still transmitted by transfusion.


Subject(s)
Antibodies, Viral/blood , Blood Donors , HIV Infections/diagnosis , Biomarkers/blood , Brazil , Enzyme-Linked Immunosorbent Assay , HIV Antibodies/blood , HIV Infections/blood , HIV Infections/transmission , HTLV-I Antibodies/blood , HTLV-II Antibodies/blood , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis C Antibodies/blood , Humans , Retrospective Studies , Sensitivity and Specificity , Syphilis Serodiagnosis
18.
Rev. Inst. Med. Trop. Säo Paulo ; 45(1): 23-27, Jan.- Feb. 2003. tab
Article in English | LILACS | ID: lil-330508

ABSTRACT

This study evaluated the usefulness of the anti-HBc, hepatitis C virus antibodies (anti-HCV), human T cell lymphotropic virus I and II antibodies (anti-HTLV I/II), serologic tests for syphilis, and surface antigen of hepatitis B virus (HBsAg) as surrogate markers for the risk for HIV infection in 80,284 serum samples from blood donors from the Blood Bank of "Hospital Universitário Regional Norte do Paraná", Londrina, Paraná State, Brazil, analyzed from July 1994 to April 2001. Among 39 blood donors with positive serology for HIV, 12 (30.8 percent) were anti-HBc positive, 10 (25.6 percent) for anti-HCV, 1 (2.6 percent) for anti-HTLV I/I, 1 (2.6 percent) was positive for syphilis, and 1 (2.6 percent) for HBsAg. Among the donors with negative serology for HIV, these markers were detected in 8,407 (10.5 percent), 441 (0.5 percent), 189 (0.2 percent), 464 (0.6 percent), and 473 (0.6 percent) samples, respectively. The difference was statistically significant (p < 0.001) for anti-HBc and anti-HCV. Although the predictive positive value for these surrogate markers were low for HIV infection, the results confirmed the anti-HBc and anti-HCV as useful surrogate markers for HIV infection thus reinforcing the maintenance of them in the screening for blood donors contributing to the prevention of the small number of cases in which HIV is still transmitted by transfusion


Subject(s)
Humans , Antibodies, Viral , Blood Donors , HIV Infections , Biomarkers , Brazil , Enzyme-Linked Immunosorbent Assay , Hepatitis B Antibodies , Hepatitis B Surface Antigens , Hepatitis C Antibodies , HIV Antibodies , HIV Infections , HTLV-I Antibodies , HTLV-II Antibodies , Retrospective Studies , Sensitivity and Specificity , Syphilis Serodiagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...